## nature portfolio

Corresponding author(s):	Yunsun Nam
Last updated by author(s):	Oct 24, 2022

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_				
C -	トつ	±ι	ct	ics
	П		<b>``</b>	11 >

n/a	Confirmed					
	The exact	e exact sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement				
	A stateme	tement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
$\boxtimes$		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
$\boxtimes$	A description of all covariates tested					
$\boxtimes$	A descript	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
$\boxtimes$	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.					
$\boxtimes$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
$\boxtimes$	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated					
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.						
Software and code						
Policy information about <u>availability of computer code</u>						
Da	ita collection	HKL3000 v.722, SerialEM v4.0.8				
Da	nta analysis	COOT v1.0.06, Phenix v1.20.1, Prism 9, Cryosparc v3.3.1, ImageJ v.1.53				
For m	r manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and					

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The atomic models for METTL1-WDR4 (8D58), METTL1-WDR4-tRNA (8D9K), METTL1-SAM (8D59), METTL1-SAH (8D5B), METTL1-WDR4-tRNA-SAM (8D9L), METTL1-WDR4-tRNA-SAH (8EGO) are deposited in the Protein Data Bank (PDB: https://www.rcsb.org/). Cryo-EM maps and masks of METTL1-WDR4-tRNA (EMD-27264), METTL1-WDR4-tRNA-SAH (EMD-27265), and METTL1-WDR4-tRNA-SAH (EMD-28108) used to build the models are deposited in the Electron Microscopy Data Bank (EMDB: https://www.ebi.ac.uk/pdbe/emdb/).

Human rese	arch part	icipants		
	•	nvolving human research participants and Sex and Gender in Research.		
Reporting on sex	and gender	N.A.		
Population chara	cteristics	N.A.		
Recruitment		N.A.		
Ethics oversight		N.A.		
Note that full informa	ation on the appi	roval of the study protocol must also be provided in the manuscript.		
Field-spe	ecific re	eporting		
Please select the or	ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences		Behavioural & social sciences Ecological, evolutionary & environmental sciences		
For a reference copy of t	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	nces st	udy design		
All studies must dis	sclose on these	points even when the disclosure is negative.		
Sample size	For all of our cryoEM structures we used many particles for single particle analysis, starting from >600,000.			
Data exclusions	As part of single particle cryo-EM workflow, particles that do not belong to the class were rejected automatically by standard algorithms (Cryosparc).			
Replication		tive biochemical assay was repeated at least 3 times. Descriptive data were also reproduced at least 3 times and the data are shown. All attempts to perform the replicates showed similar results.		
Randomization	The particles for cryoEM calculations were randomly split into two groups and similar structures were derived. For higher resolution we merged them for the final structure. For crystallography, a random 5% of the data was flagged to calculate the Rfree, to measure the fit between experimental data and the final model.			
Blinding	Most of the randomization was performed without knowledge of the experimenter how they would contribute to the final result, as the software manages them.			
<del></del>		pecific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,		
		your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp	•	·		
n/a Involved in the study  n/a Involved in the study				

Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study
$\boxtimes$	Antibodies	$\boxtimes$	ChIP-seq
$\boxtimes$	Eukaryotic cell lines	$\boxtimes$	Flow cytometry
$\boxtimes$	Palaeontology and archaeology	$\boxtimes$	MRI-based neuroimaging
$\boxtimes$	Animals and other organisms		
$\boxtimes$	Clinical data		
$\boxtimes$	Dual use research of concern		